Business Description
Dimerix Ltd
ISIN : AU000000DXB7
Description
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.37 | |||||
| Equity-to-Asset | 0.11 | |||||
| Debt-to-Equity | 0.83 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -20.5 | |||||
| 3-Year EPS without NRI Growth Rate | -17.3 | |||||
| 3-Year FCF Growth Rate | -13 | |||||
| 3-Year Book Growth Rate | -27.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.84 | |||||
| Quick Ratio | 4.84 | |||||
| Cash Ratio | 4.76 | |||||
| Days Sales Outstanding | 1169.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.5 | |||||
| Shareholder Yield % | -2.19 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -14984.21 | |||||
| Net Margin % | -8170.68 | |||||
| FCF Margin % | 511.24 | |||||
| ROE % | -260.18 | |||||
| ROA % | -83.17 | |||||
| ROIC % | -711.16 | |||||
| ROC (Joel Greenblatt) % | -239148 | |||||
| ROCE % | -261.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 83.75 | |||||
| Price-to-Tangible-Book | 83.75 | |||||
| EV-to-EBIT | -8.57 | |||||
| EV-to-EBITDA | -8.57 | |||||
| EV-to-Revenue | 1283.9 | |||||
| EV-to-FCF | 243.25 | |||||
| Earnings Yield (Greenblatt) % | -11.67 | |||||
| FCF Yield % | 0.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SBMJF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dimerix Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.089 | ||
| EPS (TTM) ($) | -0.02 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0.002 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0.002 - 0.002 | ||
| Shares Outstanding (Mil) | 549.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dimerix Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dimerix Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dimerix Ltd Frequently Asked Questions
What is Dimerix Ltd(SBMJF)'s stock price today?
The current price of SBMJF is $0.00. The 52 week high of SBMJF is $0.00 and 52 week low is $0.00.
When is next earnings date of Dimerix Ltd(SBMJF)?
The next earnings date of Dimerix Ltd(SBMJF) is .
Does Dimerix Ltd(SBMJF) pay dividends? If so, how much?
Dimerix Ltd(SBMJF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers